News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Mohamad Mohty shares long-term survival outcomes from the phase II MagnetisMM-3 study – Multiple Myeloma Hub
Photo from Mohamad Mohty/X
Jun 20, 2024, 11:53

Mohamad Mohty shares long-term survival outcomes from the phase II MagnetisMM-3 study – Multiple Myeloma Hub

Multiple Myeloma Hub shared on X/Twitter:

“CONGRESS | POSTER | EHA2024 | Mohamad Mohty shares long-term survival outcomes from the phase II MagnetisMM-3 study of elranatamab in patients with RRMM, N=123. ORR remained at 61%, with median DoR not reached.”

Mohamad Mohty shares long-term survival outcomes from the phase II MagnetisMM-3 study - Multiple Myeloma Hub

Source: Multiple Myeloma Hub/X

cancer EHA2024 elranatamab MagnetisMM-3 Mohamad Mohty Multiple Myeloma Hub OncoDaily Oncology RRMM
Special Coverage
Insight
Aug 21, 2025, 20:26
Kevin Harrington Looks Forward to CONCORDE Study Results on DNA Damage Inhibitors and Radiotherapy
Voices
Aug 21, 2025, 20:00
Raymond Mailhot: Advancing Hodgkin Lymphoma Survivor Study with NCI Funding
Voices
Aug 21, 2025, 19:28
Parvati Tiwari: Advocates Express Alarm Over NCI’s Decision to End PBTC Funding for Pediatric Brain Tumor Trials
Voices
Aug 21, 2025, 15:59
George Kumar: The interplay Between Cardiovascular Disease (CVD) and Cancer
Voices
Aug 21, 2025, 15:47
European Society of Gynaecological Oncology Announces that Applications are Open for Editor-in-Chief of IJGC
Insight
Aug 21, 2025, 15:37
Carolina Reduzzi: ctDNA Landscape Analysis Post CDK4/6 Inhibitor in HR+/HER2- Metastatic Breast Cancer
Voices
Aug 21, 2025, 15:30
Clinician-Scientists Awarded NMRC Transition Awards for Precision Lung Cancer Research - National Cancer Centre Singapore
Voices
Aug 21, 2025, 15:22
Construction of the $658 million Sydney Children’s Hospital Stage One and MCCCC Project Has Reached Completion
Oncolibrary
Aug 21, 2025, 15:00
Breakthrough Emactuzumab Phase 3 TANGENT Trial in TGCT: SynOx Pharma Reports Enrollment Completed Ahead of Schedule
Voices
Aug 21, 2025, 14:50
Andrea Apolo Highlights the Top 5 Clinical Advances in Bladder Cancer Treatment for 2024
Insight
Aug 21, 2025, 14:47
Loay Kassem: Study Reveals BRCA Mutation Rates in Egyptian Women with Breast or Ovarian Cancer
Insight
Aug 21, 2025, 14:41
Tiago Cordeiro Felismino: Exploring the Role of Neutrophil-to-Lymphocyte Ratio in Advanced HCC Treatment